Fig. 6.

P100 generates molecular signatures in embryonic stem cells (ESC) and neuronal precursor cells (NPC) in response to multiple compound treatments. The heatmap illustrates phosphosignaling signatures in ESC and NPC when treated with different classes of epigenetically active drugs including a Brd4 inhibitor, an EZH2 inhibitor, and HDAC inhibitors. As observed in the P100 validation experiments, replicates of the same drug treatment cluster together within each cell type. Additionally, molecular signatures of the same treatment cluster across NPC and ES, as seen with the Brd4 inhibitor JQ1. Neither cell type nor any drug treatment (with the exception of MS-275) depicted above was used in the development of the P100 assay.